Cancer Angiogenesis Inhibitor Market Report: Trends, Forecast and Competitive Analysis to 2031
Description
Equine Rhinopneumonitis Vaccine Market Trends and Forecast
The future of the global equine rhinopneumonitis vaccine market looks promising with opportunities in the overview, veterinary pharmacy, and online sale markets. The global equine rhinopneumonitis vaccine market is expected to grow with a CAGR of 6.1% from 2025 to 2031. The major drivers for this market are the increasing prevalence of equine diseases source and the rising animal health spending & increasing uptake of animal insurance.
Emerging Trends in the Equine Rhinopneumonitis Vaccine Market
The equine rhinopneumonitis vaccine market is shaped by a combination of technological advancements, regulatory changes, and evolving consumer needs. These emerging trends are driving innovation and shaping the market in both established and emerging equine industries worldwide.
Recent Developments in the Equine Rhinopneumonitis Vaccine Market
The equine rhinopneumonitis vaccine market has witnessed key developments aimed at enhancing the prevention of equine respiratory diseases, addressing emerging strains of viruses, and expanding vaccine accessibility worldwide.
Strategic Growth Opportunities in the Equine Rhinopneumonitis Vaccine Market
The equine rhinopneumonitis vaccine market presents significant growth opportunities across various applications, including racing, breeding, and recreational riding. Each application offers unique opportunities for manufacturers to expand their reach and improve equine health outcomes.
Equine Rhinopneumonitis Vaccine Market Driver and Challenges
The global equine rhinopneumonitis vaccine market is driven by advancements in vaccine technology, increased awareness of equine health, and regulatory changes. However, challenges such as high vaccine costs, regulatory hurdles, and the need for continuous research to address emerging strains of the virus present obstacles to market growth.
The factors responsible for driving the equine rhinopneumonitis vaccine market include:
1. Technological Advancements in Vaccine Development: Advances in vaccine technologies, including recombinant vaccines and improved adjuvants, are driving the market by increasing vaccine efficacy and safety. These developments are making vaccines more effective in preventing equine rhinopneumonitis, encouraging wider adoption across the equine industry.
2. Increasing Demand for Equine Health Products: The rising global demand for equine health products, driven by the expansion of the equine industry, particularly in sports and recreational riding, is fueling market growth. As horse owners become more health-conscious, the demand for effective vaccines is increasing.
3. Regulatory Support and Standards: Regulatory agencies around the world are enhancing vaccine safety and efficacy standards, ensuring that only the most effective and safe products reach the market. This fosters confidence in equine vaccines, driving greater market penetration.
4. Rising Awareness of Respiratory Diseases: As equine respiratory diseases, including rhinopneumonitis, become more recognized as a significant threat to equine health, owners and veterinarians are prioritizing vaccination as part of comprehensive disease prevention strategies.
5. Growing Equine Industry in Emerging Markets: The growth of the equine industry in emerging markets, particularly in Asia and Latin America, is driving demand for equine health products, including vaccines. This provides manufacturers with a large, untapped market for equine rhinopneumonitis vaccines.
Challenges in the equine rhinopneumonitis vaccine market are:
1. High Production and Vaccine Costs: The production of vaccines, especially for specialized diseases like equine rhinopneumonitis, can be costly. High production costs, along with challenges in pricing vaccines competitively, may limit access to vaccines in price-sensitive markets.
2. Regulatory Barriers: Different regions have varying regulatory standards for equine vaccines, which can delay approval processes and increase the costs associated with vaccine development. Manufacturers must navigate these complex regulatory environments to bring vaccines to market.
3. Evolving Strains of Equine Herpesvirus: The continued evolution of equine herpesvirus poses a challenge to vaccine developers. New strains may render existing vaccines less effective, requiring ongoing research and adaptation of vaccine formulations to maintain efficacy.
The global equine rhinopneumonitis vaccine market is influenced by technological advancements, regulatory changes, and increasing awareness of respiratory diseases in horses. However, challenges like high production costs, regulatory hurdles, and evolving virus strains need to be addressed for sustained market growth.
List of Equine Rhinopneumonitis Vaccine Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies equine rhinopneumonitis vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the equine rhinopneumonitis vaccine companies profiled in this report include-
The study includes a forecast for the global equine rhinopneumonitis vaccine market by type, application, and region.
Equine Rhinopneumonitis Vaccine Market by Type [Value from 2019 to 2031]:
The equine rhinopneumonitis vaccine market is evolving due to increasing awareness about equine respiratory diseases, including equine herpesvirus (EHV) infections. The demand for effective vaccines is growing, driven by the rising focus on equine health in both racing and recreational sectors. In this context, several developments across key markets, including the U.S., China, Germany, India, and Japan, are shaping the future of equine vaccination strategies.
Market Size Estimates: Equine rhinopneumonitis vaccine market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Equine rhinopneumonitis vaccine market size by type, application, and region in terms of value ($B).
Regional Analysis: Equine rhinopneumonitis vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the equine rhinopneumonitis vaccine market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the equine rhinopneumonitis vaccine market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the equine rhinopneumonitis vaccine market by type (overview, live, and inactivated), application (overview, veterinary pharmacy, online sale, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Please note: It will take 2-3 business days to deliver the report upon receipt the order.
The future of the global equine rhinopneumonitis vaccine market looks promising with opportunities in the overview, veterinary pharmacy, and online sale markets. The global equine rhinopneumonitis vaccine market is expected to grow with a CAGR of 6.1% from 2025 to 2031. The major drivers for this market are the increasing prevalence of equine diseases source and the rising animal health spending & increasing uptake of animal insurance.
- Lucintel forecasts that, within the type category, inactivated will remain the largest segment over the forecast period due to rising safety preference for inactivated vaccines due to lower risk of side effects in horses.
- Within the application category, online sales is expected to witness the higher growth due to growing adoption of digital channels by veterinary suppliers for wider reach.
- In terms of region, APAC is expected to witness the highest growth over the forecast period.
Emerging Trends in the Equine Rhinopneumonitis Vaccine Market
The equine rhinopneumonitis vaccine market is shaped by a combination of technological advancements, regulatory changes, and evolving consumer needs. These emerging trends are driving innovation and shaping the market in both established and emerging equine industries worldwide.
- Combination Vaccines: There is a growing trend toward the development of combination vaccines that target multiple pathogens, including equine herpesvirus, equine influenza, and other respiratory diseases. This trend simplifies vaccination schedules and reduces the number of injections required for horses, improving overall compliance and health outcomes.
- Advanced Vaccine Formulations: The demand for vaccines that offer longer-lasting protection against equine rhinopneumonitis is rising. Manufacturers are investing in novel adjuvants and vaccine delivery systems to increase the efficacy and duration of protection. These advanced formulations are becoming more common in the market and are expected to replace older, less effective vaccines.
- Increased Focus on Biosecurity: With the growing risk of equine respiratory outbreaks, there is an increased focus on biosecurity and preventive health. Governments and veterinary professionals are stressing the importance of vaccination programs to prevent the spread of equine herpesvirus and other respiratory infections, particularly in regions with high equine population densities.
- Regulatory Evolution: Regulatory standards for equine vaccines are becoming more stringent, with an increased emphasis on safety, efficacy, and traceability. This is driving innovation in vaccine production and encouraging manufacturers to develop high-quality, safer products to meet new regulatory guidelines in both developed and emerging markets.
- Global Expansion of Vaccine Access: As the global equine market expands, there is a greater push to make vaccines accessible in developing regions. This includes improvements in vaccine distribution networks and affordability, which is helping to prevent the spread of respiratory diseases in horses worldwide, especially in emerging economies.
Recent Developments in the Equine Rhinopneumonitis Vaccine Market
The equine rhinopneumonitis vaccine market has witnessed key developments aimed at enhancing the prevention of equine respiratory diseases, addressing emerging strains of viruses, and expanding vaccine accessibility worldwide.
- Introduction of Combination Vaccines: Recent innovations have led to the development of combination vaccines that offer protection against both equine herpesvirus and equine influenza. These vaccines simplify vaccination schedules and provide broader protection, which is critical for horses involved in competitive sports and breeding programs.
- Enhanced Vaccine Efficacy: Vaccine manufacturers have been focused on improving the efficacy of equine rhinopneumonitis vaccines. New formulations with stronger adjuvants and improved delivery mechanisms are now providing longer-lasting immunity and better protection against the virus, contributing to the overall health of the equine population.
- Stricter Regulatory Standards: Governments and regulatory bodies worldwide are tightening vaccine approval processes to ensure higher safety and efficacy. This has led to the development of vaccines that adhere to stringent standards, helping reduce adverse reactions and ensuring better compliance with international health regulations.
- Global Vaccine Accessibility: As demand for equine vaccines grows, efforts to expand vaccine accessibility in emerging markets have been a key development. Improved distribution networks and local vaccine production are helping increase availability in regions with previously limited access, thereby boosting preventive health practices in global equine communities.
- Increased Research and Development Investment: Investment in research and development for equine vaccines has been on the rise, with manufacturers dedicating resources to developing vaccines that target new or evolving strains of equine herpesvirus. This ensures that the vaccines remain effective as the virus evolves, safeguarding equine populations from emerging threats.
Strategic Growth Opportunities in the Equine Rhinopneumonitis Vaccine Market
The equine rhinopneumonitis vaccine market presents significant growth opportunities across various applications, including racing, breeding, and recreational riding. Each application offers unique opportunities for manufacturers to expand their reach and improve equine health outcomes.
- Equine Racing Industry: The equine racing industry represents a major growth opportunity due to the high value of horses in competitive sports. Ensuring the health of racehorses through vaccination is crucial, making it a priority for vaccine manufacturers to develop highly effective vaccines that protect against rhinopneumonitis and other respiratory diseases.
- Equine Breeding: Equine breeders are investing in vaccination programs to protect breeding stock from respiratory diseases, which can affect fertility and overall reproductive health. Targeted vaccines for breeding horses offer manufacturers an opportunity to develop specialized formulations that ensure the health of both stallions and mares.
- Recreational Riding and Leisure: As more individuals participate in recreational riding, the demand for equine health products, including vaccines, is growing. Vaccines that protect against rhinopneumonitis can help ensure the health and longevity of horses used for leisure, presenting a growing market for vaccine manufacturers.
- Veterinary Clinics and Health Facilities: Veterinary clinics are key to the growth of the equine rhinopneumonitis vaccine market. Offering vaccines in clinics for a broad range of equine clients—both competitive and non-competitive—helps increase vaccine uptake, providing opportunities for manufacturers to expand their distribution in these healthcare settings.
- International Markets: With the growth of equine industries in emerging economies, particularly in Asia, there is a significant opportunity for manufacturers to expand their market reach. This includes developing affordable vaccines and establishing partnerships with local distributors to increase market penetration in regions with high equine populations.
Equine Rhinopneumonitis Vaccine Market Driver and Challenges
The global equine rhinopneumonitis vaccine market is driven by advancements in vaccine technology, increased awareness of equine health, and regulatory changes. However, challenges such as high vaccine costs, regulatory hurdles, and the need for continuous research to address emerging strains of the virus present obstacles to market growth.
The factors responsible for driving the equine rhinopneumonitis vaccine market include:
1. Technological Advancements in Vaccine Development: Advances in vaccine technologies, including recombinant vaccines and improved adjuvants, are driving the market by increasing vaccine efficacy and safety. These developments are making vaccines more effective in preventing equine rhinopneumonitis, encouraging wider adoption across the equine industry.
2. Increasing Demand for Equine Health Products: The rising global demand for equine health products, driven by the expansion of the equine industry, particularly in sports and recreational riding, is fueling market growth. As horse owners become more health-conscious, the demand for effective vaccines is increasing.
3. Regulatory Support and Standards: Regulatory agencies around the world are enhancing vaccine safety and efficacy standards, ensuring that only the most effective and safe products reach the market. This fosters confidence in equine vaccines, driving greater market penetration.
4. Rising Awareness of Respiratory Diseases: As equine respiratory diseases, including rhinopneumonitis, become more recognized as a significant threat to equine health, owners and veterinarians are prioritizing vaccination as part of comprehensive disease prevention strategies.
5. Growing Equine Industry in Emerging Markets: The growth of the equine industry in emerging markets, particularly in Asia and Latin America, is driving demand for equine health products, including vaccines. This provides manufacturers with a large, untapped market for equine rhinopneumonitis vaccines.
Challenges in the equine rhinopneumonitis vaccine market are:
1. High Production and Vaccine Costs: The production of vaccines, especially for specialized diseases like equine rhinopneumonitis, can be costly. High production costs, along with challenges in pricing vaccines competitively, may limit access to vaccines in price-sensitive markets.
2. Regulatory Barriers: Different regions have varying regulatory standards for equine vaccines, which can delay approval processes and increase the costs associated with vaccine development. Manufacturers must navigate these complex regulatory environments to bring vaccines to market.
3. Evolving Strains of Equine Herpesvirus: The continued evolution of equine herpesvirus poses a challenge to vaccine developers. New strains may render existing vaccines less effective, requiring ongoing research and adaptation of vaccine formulations to maintain efficacy.
The global equine rhinopneumonitis vaccine market is influenced by technological advancements, regulatory changes, and increasing awareness of respiratory diseases in horses. However, challenges like high production costs, regulatory hurdles, and evolving virus strains need to be addressed for sustained market growth.
List of Equine Rhinopneumonitis Vaccine Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies equine rhinopneumonitis vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the equine rhinopneumonitis vaccine companies profiled in this report include-
- Merck & Co
- Esaote SPA
- Covetrus
- Elanco
- Cargill
The study includes a forecast for the global equine rhinopneumonitis vaccine market by type, application, and region.
Equine Rhinopneumonitis Vaccine Market by Type [Value from 2019 to 2031]:
- Overview
- Live
- Inactivated
- Overview
- Veterinary Pharmacy
- Online Sale
- Others
- North America
- Europe
- Asia Pacific
- The Rest of the World
The equine rhinopneumonitis vaccine market is evolving due to increasing awareness about equine respiratory diseases, including equine herpesvirus (EHV) infections. The demand for effective vaccines is growing, driven by the rising focus on equine health in both racing and recreational sectors. In this context, several developments across key markets, including the U.S., China, Germany, India, and Japan, are shaping the future of equine vaccination strategies.
- United States: In the U.S., the equine rhinopneumonitis vaccine market has seen significant advancements, with a focus on improving vaccine efficacy against equine herpesvirus types 1 and 4 (EHV-1, EHV-4). The introduction of combination vaccines, which protect against multiple equine respiratory pathogens, is becoming increasingly popular. Additionally, the U.S. has strengthened regulatory standards for equine vaccines, encouraging more research and development into improved formulations to combat evolving strains of the virus.
- China: China’s equine rhinopneumonitis vaccine market is growing as the country's equine industry expands. Increased domestic production of vaccines has led to greater accessibility and affordability for Chinese horse owners. The Chinese government is also implementing stricter animal health regulations, which are contributing to the rising demand for vaccines. Additionally, advancements in vaccine distribution networks are ensuring that vaccines are more widely available, leading to better prevention of respiratory diseases in horses.
- Germany: Germany has been a leader in equine veterinary care, with an emphasis on improving vaccine formulations for equine rhinopneumonitis. In recent years, there has been a push for more comprehensive and long-lasting vaccines, as well as vaccines that can be administered in combination with other equine health vaccines. Germany’s well-regulated veterinary market supports high-quality research and development, which is ensuring that its equine rhinopneumonitis vaccines meet both domestic and international standards.
- India: In India, the market for equine rhinopneumonitis vaccines is gradually growing, driven by increasing equine populations and improved awareness of equine respiratory diseases. Government initiatives to improve animal health standards and a growing interest in equine racing and recreational industries are further fueling demand. Vaccine manufacturers are focusing on making vaccines more affordable and accessible to cater to the needs of both urban and rural equine communities in India.
- Japan: Japan’s equine rhinopneumonitis vaccine market is supported by a well-established equine sector, especially in racing and sports. Vaccination is a key part of preventive healthcare for horses, and recent developments include innovations in vaccine formulations that provide broader protection against respiratory diseases. Japan is also focusing on expanding vaccine distribution systems, ensuring that rural and urban equine populations have equal access to these critical health products.
Market Size Estimates: Equine rhinopneumonitis vaccine market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Equine rhinopneumonitis vaccine market size by type, application, and region in terms of value ($B).
Regional Analysis: Equine rhinopneumonitis vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the equine rhinopneumonitis vaccine market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the equine rhinopneumonitis vaccine market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the equine rhinopneumonitis vaccine market by type (overview, live, and inactivated), application (overview, veterinary pharmacy, online sale, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Please note: It will take 2-3 business days to deliver the report upon receipt the order.
Table of Contents
150 Pages
- 1. Executive Summary
- 2. Market Overview
- 2.1 Background and Classifications
- 2.2 Supply Chain
- 3. Market Trends & Forecast Analysis
- 3.1 Global Cancer Angiogenesis Inhibitor Market Trends and Forecast
- 3.2 Industry Drivers and Challenges
- 3.3 PESTLE Analysis
- 3.4 Patent Analysis
- 3.5 Regulatory Environment
- 4. Global Cancer Angiogenesis Inhibitor Market by Type
- 4.1 Overview
- 4.2 Attractiveness Analysis by Type
- 4.3 VEGF Targeted Therapy: Trends and Forecast (2019-2031)
- 4.4 FGF Targeted Therapies: Trends and Forecast (2019-2031)
- 4.5 Oncogene Targeted Therapy: Trends and Forecast (2019-2031)
- 4.6 Matrix Degrading & Remodeling Targeted Therapy: Trends and Forecast (2019-2031)
- 4.7 Others: Trends and Forecast (2019-2031)
- 5. Global Cancer Angiogenesis Inhibitor Market by Application
- 5.1 Overview
- 5.2 Attractiveness Analysis by Application
- 5.3 Cancer: Trends and Forecast (2019-2031)
- 5.4 Interferon Alpha-2α: Trends and Forecast (2019-2031)
- 5.5 Ocular Neovascularization: Trends and Forecast (2019-2031)
- 6. Regional Analysis
- 6.1 Overview
- 6.2 Global Cancer Angiogenesis Inhibitor Market by Region
- 7. North American Cancer Angiogenesis Inhibitor Market
- 7.1 Overview
- 7.2 North American Cancer Angiogenesis Inhibitor Market by Type
- 7.3 North American Cancer Angiogenesis Inhibitor Market by Application
- 7.4 United States Cancer Angiogenesis Inhibitor Market
- 7.5 Mexican Cancer Angiogenesis Inhibitor Market
- 7.6 Canadian Cancer Angiogenesis Inhibitor Market
- 8. European Cancer Angiogenesis Inhibitor Market
- 8.1 Overview
- 8.2 European Cancer Angiogenesis Inhibitor Market by Type
- 8.3 European Cancer Angiogenesis Inhibitor Market by Application
- 8.4 German Cancer Angiogenesis Inhibitor Market
- 8.5 French Cancer Angiogenesis Inhibitor Market
- 8.6 Spanish Cancer Angiogenesis Inhibitor Market
- 8.7 Italian Cancer Angiogenesis Inhibitor Market
- 8.8 United Kingdom Cancer Angiogenesis Inhibitor Market
- 9. APAC Cancer Angiogenesis Inhibitor Market
- 9.1 Overview
- 9.2 APAC Cancer Angiogenesis Inhibitor Market by Type
- 9.3 APAC Cancer Angiogenesis Inhibitor Market by Application
- 9.4 Japanese Cancer Angiogenesis Inhibitor Market
- 9.5 Indian Cancer Angiogenesis Inhibitor Market
- 9.6 Chinese Cancer Angiogenesis Inhibitor Market
- 9.7 South Korean Cancer Angiogenesis Inhibitor Market
- 9.8 Indonesian Cancer Angiogenesis Inhibitor Market
- 10. ROW Cancer Angiogenesis Inhibitor Market
- 10.1 Overview
- 10.2 ROW Cancer Angiogenesis Inhibitor Market by Type
- 10.3 ROW Cancer Angiogenesis Inhibitor Market by Application
- 10.4 Middle Eastern Cancer Angiogenesis Inhibitor Market
- 10.5 South American Cancer Angiogenesis Inhibitor Market
- 10.6 African Cancer Angiogenesis Inhibitor Market
- 11. Competitor Analysis
- 11.1 Product Portfolio Analysis
- 11.2 Operational Integration
- 11.3 Porter’s Five Forces Analysis
- • Competitive Rivalry
- • Bargaining Power of Buyers
- • Bargaining Power of Suppliers
- • Threat of Substitutes
- • Threat of New Entrants
- 11.4 Market Share Analysis
- 12. Opportunities & Strategic Analysis
- 12.1 Value Chain Analysis
- 12.2 Growth Opportunity Analysis
- 12.2.1 Growth Opportunities by Type
- 12.2.2 Growth Opportunities by Application
- 12.3 Emerging Trends in the Global Cancer Angiogenesis Inhibitor Market
- 12.4 Strategic Analysis
- 12.4.1 New Product Development
- 12.4.2 Certification and Licensing
- 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures
- 13. Company Profiles of the Leading Players Across the Value Chain
- 13.1 Competitive Analysis
- 13.2 Intas Pharmaceuticals
- • Company Overview
- • Cancer Angiogenesis Inhibitor Business Overview
- • New Product Development
- • Merger, Acquisition, and Collaboration
- • Certification and Licensing
- 13.3 Kyowa Hakko Kirin
- • Company Overview
- • Cancer Angiogenesis Inhibitor Business Overview
- • New Product Development
- • Merger, Acquisition, and Collaboration
- • Certification and Licensing
- 13.4 Levolta Pharmaceuticals
- • Company Overview
- • Cancer Angiogenesis Inhibitor Business Overview
- • New Product Development
- • Merger, Acquisition, and Collaboration
- • Certification and Licensing
- 13.5 Mabtech
- • Company Overview
- • Cancer Angiogenesis Inhibitor Business Overview
- • New Product Development
- • Merger, Acquisition, and Collaboration
- • Certification and Licensing
- 13.6 Marsala Biotech
- • Company Overview
- • Cancer Angiogenesis Inhibitor Business Overview
- • New Product Development
- • Merger, Acquisition, and Collaboration
- • Certification and Licensing
- 13.7 Neumedicines
- • Company Overview
- • Cancer Angiogenesis Inhibitor Business Overview
- • New Product Development
- • Merger, Acquisition, and Collaboration
- • Certification and Licensing
- 13.8 Genentech
- • Company Overview
- • Cancer Angiogenesis Inhibitor Business Overview
- • New Product Development
- • Merger, Acquisition, and Collaboration
- • Certification and Licensing
- 13.9 Five Prime Therapeutics
- • Company Overview
- • Cancer Angiogenesis Inhibitor Business Overview
- • New Product Development
- • Merger, Acquisition, and Collaboration
- • Certification and Licensing
- 14. Appendix
- 14.1 List of Figures
- 14.2 List of Tables
- 14.3 Research Methodology
- 14.4 Disclaimer
- 14.5 Copyright
- 14.6 Abbreviations and Technical Units
- 14.7 About Us
- 14.8 Contact Us
- List of Figures
- Chapter 1
- Figure 1.1: Trends and Forecast for the Global Cancer Angiogenesis Inhibitor Market
- Chapter 2
- Figure 2.1: Usage of Cancer Angiogenesis Inhibitor Market
- Figure 2.2: Classification of the Global Cancer Angiogenesis Inhibitor Market
- Figure 2.3: Supply Chain of the Global Cancer Angiogenesis Inhibitor Market
- Chapter 3
- Figure 3.1: Driver and Challenges of the Cancer Angiogenesis Inhibitor Market
- Figure 3.2: PESTLE Analysis
- Figure 3.3: Patent Analysis
- Figure 3.4: Regulatory Environment
- Chapter 4
- Figure 4.1: Global Cancer Angiogenesis Inhibitor Market by Type in 2019, 2024, and 2031
- Figure 4.2: Trends of the Global Cancer Angiogenesis Inhibitor Market ($B) by Type
- Figure 4.3: Forecast for the Global Cancer Angiogenesis Inhibitor Market ($B) by Type
- Figure 4.4: Trends and Forecast for VEGF Targeted Therapy in the Global Cancer Angiogenesis Inhibitor Market (2019-2031)
- Figure 4.5: Trends and Forecast for FGF Targeted Therapies in the Global Cancer Angiogenesis Inhibitor Market (2019-2031)
- Figure 4.6: Trends and Forecast for Oncogene Targeted Therapy in the Global Cancer Angiogenesis Inhibitor Market (2019-2031)
- Figure 4.7: Trends and Forecast for Matrix Degrading & Remodeling Targeted Therapy in the Global Cancer Angiogenesis Inhibitor Market (2019-2031)
- Figure 4.8: Trends and Forecast for Others in the Global Cancer Angiogenesis Inhibitor Market (2019-2031)
- Chapter 5
- Figure 5.1: Global Cancer Angiogenesis Inhibitor Market by Application in 2019, 2024, and 2031
- Figure 5.2: Trends of the Global Cancer Angiogenesis Inhibitor Market ($B) by Application
- Figure 5.3: Forecast for the Global Cancer Angiogenesis Inhibitor Market ($B) by Application
- Figure 5.4: Trends and Forecast for Cancer in the Global Cancer Angiogenesis Inhibitor Market (2019-2031)
- Figure 5.5: Trends and Forecast for Interferon Alpha-2α in the Global Cancer Angiogenesis Inhibitor Market (2019-2031)
- Figure 5.6: Trends and Forecast for Ocular Neovascularization in the Global Cancer Angiogenesis Inhibitor Market (2019-2031)
- Chapter 6
- Figure 6.1: Trends of the Global Cancer Angiogenesis Inhibitor Market ($B) by Region (2019-2024)
- Figure 6.2: Forecast for the Global Cancer Angiogenesis Inhibitor Market ($B) by Region (2025-2031)
- Chapter 7
- Figure 7.1: North American Cancer Angiogenesis Inhibitor Market by Type in 2019, 2024, and 2031
- Figure 7.2: Trends of the North American Cancer Angiogenesis Inhibitor Market ($B) by Type (2019-2024)
- Figure 7.3: Forecast for the North American Cancer Angiogenesis Inhibitor Market ($B) by Type (2025-2031)
- Figure 7.4: North American Cancer Angiogenesis Inhibitor Market by Application in 2019, 2024, and 2031
- Figure 7.5: Trends of the North American Cancer Angiogenesis Inhibitor Market ($B) by Application (2019-2024)
- Figure 7.6: Forecast for the North American Cancer Angiogenesis Inhibitor Market ($B) by Application (2025-2031)
- Figure 7.7: Trends and Forecast for the United States Cancer Angiogenesis Inhibitor Market ($B) (2019-2031)
- Figure 7.8: Trends and Forecast for the Mexican Cancer Angiogenesis Inhibitor Market ($B) (2019-2031)
- Figure 7.9: Trends and Forecast for the Canadian Cancer Angiogenesis Inhibitor Market ($B) (2019-2031)
- Chapter 8
- Figure 8.1: European Cancer Angiogenesis Inhibitor Market by Type in 2019, 2024, and 2031
- Figure 8.2: Trends of the European Cancer Angiogenesis Inhibitor Market ($B) by Type (2019-2024)
- Figure 8.3: Forecast for the European Cancer Angiogenesis Inhibitor Market ($B) by Type (2025-2031)
- Figure 8.4: European Cancer Angiogenesis Inhibitor Market by Application in 2019, 2024, and 2031
- Figure 8.5: Trends of the European Cancer Angiogenesis Inhibitor Market ($B) by Application (2019-2024)
- Figure 8.6: Forecast for the European Cancer Angiogenesis Inhibitor Market ($B) by Application (2025-2031)
- Figure 8.7: Trends and Forecast for the German Cancer Angiogenesis Inhibitor Market ($B) (2019-2031)
- Figure 8.8: Trends and Forecast for the French Cancer Angiogenesis Inhibitor Market ($B) (2019-2031)
- Figure 8.9: Trends and Forecast for the Spanish Cancer Angiogenesis Inhibitor Market ($B) (2019-2031)
- Figure 8.10: Trends and Forecast for the Italian Cancer Angiogenesis Inhibitor Market ($B) (2019-2031)
- Figure 8.11: Trends and Forecast for the United Kingdom Cancer Angiogenesis Inhibitor Market ($B) (2019-2031)
- Chapter 9
- Figure 9.1: APAC Cancer Angiogenesis Inhibitor Market by Type in 2019, 2024, and 2031
- Figure 9.2: Trends of the APAC Cancer Angiogenesis Inhibitor Market ($B) by Type (2019-2024)
- Figure 9.3: Forecast for the APAC Cancer Angiogenesis Inhibitor Market ($B) by Type (2025-2031)
- Figure 9.4: APAC Cancer Angiogenesis Inhibitor Market by Application in 2019, 2024, and 2031
- Figure 9.5: Trends of the APAC Cancer Angiogenesis Inhibitor Market ($B) by Application (2019-2024)
- Figure 9.6: Forecast for the APAC Cancer Angiogenesis Inhibitor Market ($B) by Application (2025-2031)
- Figure 9.7: Trends and Forecast for the Japanese Cancer Angiogenesis Inhibitor Market ($B) (2019-2031)
- Figure 9.8: Trends and Forecast for the Indian Cancer Angiogenesis Inhibitor Market ($B) (2019-2031)
- Figure 9.9: Trends and Forecast for the Chinese Cancer Angiogenesis Inhibitor Market ($B) (2019-2031)
- Figure 9.10: Trends and Forecast for the South Korean Cancer Angiogenesis Inhibitor Market ($B) (2019-2031)
- Figure 9.11: Trends and Forecast for the Indonesian Cancer Angiogenesis Inhibitor Market ($B) (2019-2031)
- Chapter 10
- Figure 10.1: ROW Cancer Angiogenesis Inhibitor Market by Type in 2019, 2024, and 2031
- Figure 10.2: Trends of the ROW Cancer Angiogenesis Inhibitor Market ($B) by Type (2019-2024)
- Figure 10.3: Forecast for the ROW Cancer Angiogenesis Inhibitor Market ($B) by Type (2025-2031)
- Figure 10.4: ROW Cancer Angiogenesis Inhibitor Market by Application in 2019, 2024, and 2031
- Figure 10.5: Trends of the ROW Cancer Angiogenesis Inhibitor Market ($B) by Application (2019-2024)
- Figure 10.6: Forecast for the ROW Cancer Angiogenesis Inhibitor Market ($B) by Application (2025-2031)
- Figure 10.7: Trends and Forecast for the Middle Eastern Cancer Angiogenesis Inhibitor Market ($B) (2019-2031)
- Figure 10.8: Trends and Forecast for the South American Cancer Angiogenesis Inhibitor Market ($B) (2019-2031)
- Figure 10.9: Trends and Forecast for the African Cancer Angiogenesis Inhibitor Market ($B) (2019-2031)
- Chapter 11
- Figure 11.1: Porter’s Five Forces Analysis of the Global Cancer Angiogenesis Inhibitor Market
- Figure 11.2: Market Share (%) of Top Players in the Global Cancer Angiogenesis Inhibitor Market (2024)
- Chapter 12
- Figure 12.1: Growth Opportunities for the Global Cancer Angiogenesis Inhibitor Market by Type
- Figure 12.2: Growth Opportunities for the Global Cancer Angiogenesis Inhibitor Market by Application
- Figure 12.3: Growth Opportunities for the Global Cancer Angiogenesis Inhibitor Market by Region
- Figure 12.4: Emerging Trends in the Global Cancer Angiogenesis Inhibitor Market
- List of Tables
- Chapter 1
- Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Cancer Angiogenesis Inhibitor Market by Type and Application
- Table 1.2: Attractiveness Analysis for the Cancer Angiogenesis Inhibitor Market by Region
- Table 1.3: Global Cancer Angiogenesis Inhibitor Market Parameters and Attributes
- Chapter 3
- Table 3.1: Trends of the Global Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 3.2: Forecast for the Global Cancer Angiogenesis Inhibitor Market (2025-2031)
- Chapter 4
- Table 4.1: Attractiveness Analysis for the Global Cancer Angiogenesis Inhibitor Market by Type
- Table 4.2: Market Size and CAGR of Various Type in the Global Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 4.3: Market Size and CAGR of Various Type in the Global Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 4.4: Trends of VEGF Targeted Therapy in the Global Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 4.5: Forecast for VEGF Targeted Therapy in the Global Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 4.6: Trends of FGF Targeted Therapies in the Global Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 4.7: Forecast for FGF Targeted Therapies in the Global Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 4.8: Trends of Oncogene Targeted Therapy in the Global Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 4.9: Forecast for Oncogene Targeted Therapy in the Global Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 4.10: Trends of Matrix Degrading & Remodeling Targeted Therapy in the Global Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 4.11: Forecast for Matrix Degrading & Remodeling Targeted Therapy in the Global Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 4.12: Trends of Others in the Global Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 4.13: Forecast for Others in the Global Cancer Angiogenesis Inhibitor Market (2025-2031)
- Chapter 5
- Table 5.1: Attractiveness Analysis for the Global Cancer Angiogenesis Inhibitor Market by Application
- Table 5.2: Market Size and CAGR of Various Application in the Global Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 5.3: Market Size and CAGR of Various Application in the Global Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 5.4: Trends of Cancer in the Global Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 5.5: Forecast for Cancer in the Global Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 5.6: Trends of Interferon Alpha-2α in the Global Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 5.7: Forecast for Interferon Alpha-2α in the Global Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 5.8: Trends of Ocular Neovascularization in the Global Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 5.9: Forecast for Ocular Neovascularization in the Global Cancer Angiogenesis Inhibitor Market (2025-2031)
- Chapter 6
- Table 6.1: Market Size and CAGR of Various Regions in the Global Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 6.2: Market Size and CAGR of Various Regions in the Global Cancer Angiogenesis Inhibitor Market (2025-2031)
- Chapter 7
- Table 7.1: Trends of the North American Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 7.2: Forecast for the North American Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 7.3: Market Size and CAGR of Various Type in the North American Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 7.4: Market Size and CAGR of Various Type in the North American Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 7.5: Market Size and CAGR of Various Application in the North American Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 7.6: Market Size and CAGR of Various Application in the North American Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 7.7: Trends and Forecast for the United States Cancer Angiogenesis Inhibitor Market (2019-2031)
- Table 7.8: Trends and Forecast for the Mexican Cancer Angiogenesis Inhibitor Market (2019-2031)
- Table 7.9: Trends and Forecast for the Canadian Cancer Angiogenesis Inhibitor Market (2019-2031)
- Chapter 8
- Table 8.1: Trends of the European Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 8.2: Forecast for the European Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 8.3: Market Size and CAGR of Various Type in the European Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 8.4: Market Size and CAGR of Various Type in the European Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 8.5: Market Size and CAGR of Various Application in the European Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 8.6: Market Size and CAGR of Various Application in the European Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 8.7: Trends and Forecast for the German Cancer Angiogenesis Inhibitor Market (2019-2031)
- Table 8.8: Trends and Forecast for the French Cancer Angiogenesis Inhibitor Market (2019-2031)
- Table 8.9: Trends and Forecast for the Spanish Cancer Angiogenesis Inhibitor Market (2019-2031)
- Table 8.10: Trends and Forecast for the Italian Cancer Angiogenesis Inhibitor Market (2019-2031)
- Table 8.11: Trends and Forecast for the United Kingdom Cancer Angiogenesis Inhibitor Market (2019-2031)
- Chapter 9
- Table 9.1: Trends of the APAC Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 9.2: Forecast for the APAC Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 9.3: Market Size and CAGR of Various Type in the APAC Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 9.4: Market Size and CAGR of Various Type in the APAC Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 9.5: Market Size and CAGR of Various Application in the APAC Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 9.6: Market Size and CAGR of Various Application in the APAC Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 9.7: Trends and Forecast for the Japanese Cancer Angiogenesis Inhibitor Market (2019-2031)
- Table 9.8: Trends and Forecast for the Indian Cancer Angiogenesis Inhibitor Market (2019-2031)
- Table 9.9: Trends and Forecast for the Chinese Cancer Angiogenesis Inhibitor Market (2019-2031)
- Table 9.10: Trends and Forecast for the South Korean Cancer Angiogenesis Inhibitor Market (2019-2031)
- Table 9.11: Trends and Forecast for the Indonesian Cancer Angiogenesis Inhibitor Market (2019-2031)
- Chapter 10
- Table 10.1: Trends of the ROW Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 10.2: Forecast for the ROW Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 10.3: Market Size and CAGR of Various Type in the ROW Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 10.4: Market Size and CAGR of Various Type in the ROW Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 10.5: Market Size and CAGR of Various Application in the ROW Cancer Angiogenesis Inhibitor Market (2019-2024)
- Table 10.6: Market Size and CAGR of Various Application in the ROW Cancer Angiogenesis Inhibitor Market (2025-2031)
- Table 10.7: Trends and Forecast for the Middle Eastern Cancer Angiogenesis Inhibitor Market (2019-2031)
- Table 10.8: Trends and Forecast for the South American Cancer Angiogenesis Inhibitor Market (2019-2031)
- Table 10.9: Trends and Forecast for the African Cancer Angiogenesis Inhibitor Market (2019-2031)
- Chapter 11
- Table 11.1: Product Mapping of Cancer Angiogenesis Inhibitor Suppliers Based on Segments
- Table 11.2: Operational Integration of Cancer Angiogenesis Inhibitor Manufacturers
- Table 11.3: Rankings of Suppliers Based on Cancer Angiogenesis Inhibitor Revenue
- Chapter 12
- Table 12.1: New Product Launches by Major Cancer Angiogenesis Inhibitor Producers (2019-2024)
- Table 12.2: Certification Acquired by Major Competitor in the Global Cancer Angiogenesis Inhibitor Market
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.